[The Grenelle of MR contrast agents?].
Clément
O
O
D003287:Contrast Media / Q000009:adverse effects*; D005060:Europe; D005355:Fibrosis / Q000139:chemically induced*; D005682:Gadolinium; D019786:Gadolinium DTPA / Q000009:adverse effects; D006571:Heterocyclic Compounds / Q000009:adverse effects; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008536:Meglumine / Q000009:adverse effects; D009942:Organometallic Compounds / Q000009:adverse effects; D011358:Product Surveillance, Postmarketing; D051437:Renal Insufficiency / Q000150:complications*; D014481:United States; D014486:United States Food and Drug Administration
D003287:Contrast Media; D006571:Heterocyclic Compounds; D009942:Organometallic Compounds; C062402:gadoteridol; C090600:gadobutrol; D008536:Meglumine; D005682:Gadolinium; D019786:Gadolinium DTPA; C072417:gadoterate meglumine